KASEY DUNN: Open Payments
NPI 1588286389 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$864 in 43 payments from 22 companies in 2025. Trend: 2023 $477 · 2024 $805 · 2025 $864
Food & beverage: $864
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $141 |
| Novartis Pharmaceuticals Corporation | 4 | $74 |
| Celgene Corporation | 3 | $66 |
| Janssen Biotech, Inc. | 3 | $64 |
| E.R. Squibb & Sons, L.L.C. | 3 | $56 |
| PFIZER INC. | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Stemline Therapeutics Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| GlaxoSmithKline, LLC. | 2 | $35 |
Products named: REBLOZYL, OPDIVO, IBRANCE, LYNPARZA, ENHERTU, Orserdu, NINLARO, SCEMBLIX.
Industry payments across LA — which companies pay providers there.
